About a quarter of the phase 3 trials presented at ASCO annual meetings are either unpublished or publication has been greatly delayed. br / iMedscape Medical News/i
In this Expert Interview from ASH 2007, Dr. Jorge Cortes discusses new and follow-up data from clinical trials of drug therapies for CML. Medscape Hematology-Oncology
Dr. Maurie Markman comments on a study in The New England Journal of Medicine demonstrating a significant benefit with gefitinib over standard chemotherapy in metastatic non-small-cell lung cancer. Medscape Genomic Medicine